Essay: The political logic of regulatory error

Nature Reviews Drug Discovery

Volumn 4, Issue 10, 2005, Pages 819-823

  Carpenter, Daniel ^a   Ting, Michael M ^b  

^a HARVARD UNIVERSITY   (United States)

^b Department of Political Science ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NEW DRUG; OXPRENOLOL; PROPRANOLOL; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; COST OF ILLNESS; DECISION MAKING; DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; OSTEOARTHRITIS; PRIORITY JOURNAL; REGULATORY ERROR; RISK BENEFIT ANALYSIS; SIDE EFFECT;

DRUG APPROVAL; HUMANS; LACTONES; LOGIC; OBSERVER VARIATION; POLITICS; RESEARCH DESIGN; SULFONES;

EID: 27644588840     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1850     Document Type: Article

References (15)

1. Wardell, W. M. A Close inspection of the calm look. J. Am. Med. Assoc. 239, 2004-2011 (1978).
2. Carpenter, D. P. Groups, the media, agency waiting costs and fda drug approval. Am. J. Political Sci. 46, 490-505 (2002).
3. Carpenter, D. P. Protection without capture: Dynamic product approval by a politically responsive, learning regulator. Am. Political Sci. Rev. 98, 613-631 (2004).
4. Carpenter, D. P. & Ting, M. M. Regulatory error under two-sided uncertainty (unpublished manuscript, Department of Government, Harvard University; circulated as Robert Wood Johnson Scholars in Health Policy Program Working Paper #30) (2005).
5. Hilts, P. Protecting America's Health: The FDA, Business and One Hundred Years of Regulation (Knopf, New York, 2003).
6. Carpenter, D. P. The political economy of FDA drug approval: Processing, politics and lessons for policy. Health Affairs 23, 52-63 (2004).
7. Carpenter, D. P., Chernew, M., Fendrick, A. M. & Smith, D. Approval times for new drugs: Does the source of funding for FDA staff matter?' Health Affairs (web exclusive), W3-618-624 (2003).
8. Psaty, B. M., Furberg, C. D., Ray, W. A., Weiss, N. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis. JAMA 292, 2630 (2004).
9. Wood, A. J., Stein, C. M. & Woosley, R. Making medicines safer: The need for an independent drug safety board. N. Engl. J. Med. 339, 1851-1854 (1998).
10. Senator Charles Grassley, remarks on 'Food and Drug Administration' radio programme. Diane Rehm Show [online audio], (23 November 2004).
11. Wardell, W. & Lasagna, F. Regulation and Drug Development (American Enterprise Institute, Washington DC, 1975).
12. Graham, D. FDA, Merck and Vioxx: Putting patient safety first? [online],
13. Carpenter, D. P. & Fendrick, A. M. Accelerating approval times for new drugs in the United States. The Regulatory Affairs J. Pharma. 15, 411-417 (2004).
14. Peltzman, S. Regulation of Pharmaceutical Innovation: The 1962 Amendments Washington: (American Enterprise Institute for Public Policy Research, Washington DC, 1974).
15. Ting, M. M. A strategic theory of bureaucratic redundancy. Am. J. Political Sci. 47, 274-292 (2003).